KMDA KAMADA LTD IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1567529 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.1%
TTM net income YoY39.7%
TTM EPS YoY40.0%
Revenue 3-yr CAGR-0.1%
Net income 3-yr CAGR—
Margins
Gross margin42.3%
Operating margin14.5%
Net margin11.2%
FCF margin—
EBITDA margin15.4%
Returns
ROE7.6%
ROA5.4%
ROIC (approx.)12.1%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets29.0%
Debt / equity0.00x
Current ratio4.07x
Interest coverage30.36x
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio-1.4%
Payout ratio114.2%
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $180.46M | $160.95M | $142.52M | $129.34M | $103.64M |
| Cost of revenue | $104.05M | $90.99M | $87.03M | $82.64M | $73.31M |
| Gross profit | $76.41M | $69.97M | $55.49M | $46.70M | $30.33M |
| R&D expense | $12.99M | $15.19M | $13.93M | $13.17M | $11.36M |
| SG&A expense | $18.72M | $15.70M | $14.38M | $12.80M | $12.64M |
| Operating income | $26.23M | $20.05M | $10.06M | $4.53M | -$696,000 |
| Interest expense | $864,000 | $660,000 | $1.30M | $914,000 | $283,000 |
| Pretax income | $23.47M | $13.33M | $8.43M | -$2.26M | -$1.89M |
| Income tax | $3.27M | -$1.13M | $145,000 | $62,000 | $345,000 |
| Net income | $20.20M | $14.46M | $8.28M | -$2.32M | -$2.23M |
| EBITDA | $27.87M | $21.54M | $22.78M | $16.69M | $4.91M |
| EPS (basic) | 0.35 | 0.25 | 0.17 | -0.05 | -0.05 |
| EPS (diluted) | 0.35 | 0.25 | 0.15 | -0.05 | -0.05 |
| Weighted avg. shares (diluted) | 58.35M | 57.82M | 53.68M | 44.86M | 44.90M |
| Balance sheet | |||||
| Cash & equivalents | $75.47M | $78.44M | $55.64M | $34.26M | $18.59M |
| Receivables | $27.01M | $21.55M | $19.88M | $27.25M | $35.16M |
| Inventory | $84.94M | $78.82M | $88.48M | $68.78M | $67.42M |
| Current assets | $193.07M | $184.35M | $169.96M | $139.00M | $130.04M |
| PP&E, netmay include right-of-use assets (IFRS) | $41.37M | $36.24M | $28.22M | $26.16M | $26.31M |
| Goodwill | $30.31M | $30.31M | $30.31M | $147.01M | — |
| Intangibles | — | — | $140.47M | $147,072 | $154.43M |
| Total assets | $378.71M | $372.25M | $354.91M | $322.38M | $318.67M |
| Current liabilities | $47.39M | $49.39M | $49.59M | $75.70M | $54.06M |
| Short-term debt | $9.92M | $10.18M | $15.00M | $4.44M | $2.63M |
| Long-term debt | — | — | — | $17.41M | $20.04M |
| Total debt | — | — | — | $21.85M | $22.67M |
| Total liabilities | $109.64M | $112.79M | $110.89M | $146.36M | $141.84M |
| Shareholders' equity | $269.07M | $259.46M | $244.02M | $176.02M | $176.82M |
| Net debt | — | — | — | -$12.41M | $4.08M |
| Shares outstanding | 57.69M | 57.51M | 57.48M | 44.83M | 44.80M |
| Cash flow statement | |||||
| Operating cash flow | $25.49M | $47.59M | $4.32M | $28.59M | -$8.82M |
| Investing cash flow | -$9.84M | -$10.74M | -$5.84M | -$3.78M | -$61.05M |
| Financing cash flow | -$18.34M | -$13.91M | $22.68M | -$9.34M | $18.59M |
| Depreciation & amortization | $1.64M | $1.49M | $12.71M | $12.15M | $5.61M |
| Stock-based compensation | $845,000 | $874,000 | $1.31M | $1.15M | $529,000 |
| Dividends paid | $11.53M | — | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.